<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741154</url>
  </required_header>
  <id_info>
    <org_study_id>MUH 20167</org_study_id>
    <secondary_id>MUH20167</secondary_id>
    <nct_id>NCT02741154</nct_id>
  </id_info>
  <brief_title>Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI</brief_title>
  <acronym>AIPRICSI</acronym>
  <official_title>Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI(Intracytoplasmic Sperm Injection) a Case Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      study the effect of aromataze inhibitor induction together with short stimulation protocol by
      gonadotrphin releasing hormon antagonist in cases that expected to be poor responder before
      ICSI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized case control study will be conducted in Maternity hospital
      IVF unite Minia University after being approved by local ethical committee of obstetrics and
      gynecology department faculty of medicine, all study details will be explained to patients
      and informed consent will be obtained before inclusion in the study . enrolled patients will
      be randomized into two groups using simple randomization by sealed opaque envelops contain
      serial computer generated numbers Control group will receive HMG 300 IU daily start at first
      day of menses with follow up by trans vaginal ultrasound (TVUS ) when at least three
      follicles reach 14mm diameter GnRh antagonist given 0.1 ml continue follow up when at least
      three follicles reach 17mm in diameter ovum pickup will done under TVUS guide if less than
      three follicles cycle will be cancelled .

      Study group will receive same management plus letrozole 2.5mg daily start at the first day of
      menses for 5 days and continue with same protocol
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 12, 2016</start_date>
  <completion_date type="Actual">September 3, 2017</completion_date>
  <primary_completion_date type="Actual">August 24, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of follicles per cycle that reach more than 17mm in diameter(quantity of ova)</measure>
    <time_frame>day of HCG injection</time_frame>
    <description>measurement of the diameter of follicles by transvaginal ultrasoundand description of diameter in report</description>
  </primary_outcome>
  <primary_outcome>
    <measure>quality of ova</measure>
    <time_frame>day of ovum pick up</time_frame>
    <description>After ova picking up examination of all ova under microscope and report how many ova reach metaphase II (quality) if more than 3 ova reach metaphase II considered satisfactory quality of ova in the current cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>14 days after ovum pick up</time_frame>
    <description>presence of clinical pregnancy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Infertility Indicated for ICSI</condition>
  <arm_group>
    <arm_group_label>aromataze group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive induction with HMG plus aromataze inhibitor plus GnRh antagonist plus HCG injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>classic group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>same protocol for induction without aromataze inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction with aromataze inhibitor</intervention_name>
    <description>letrozole 2.5mg once daily start in the first day of menses for 5days</description>
    <arm_group_label>aromataze group</arm_group_label>
    <other_name>letrozole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMG</intervention_name>
    <description>HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter</description>
    <arm_group_label>aromataze group</arm_group_label>
    <arm_group_label>classic group</arm_group_label>
    <other_name>merional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRh a</intervention_name>
    <description>antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection</description>
    <arm_group_label>aromataze group</arm_group_label>
    <arm_group_label>classic group</arm_group_label>
    <other_name>decapeptyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCG</intervention_name>
    <description>10.000 IU HCG injection when at least three follicles reach 17mm in diameter</description>
    <arm_group_label>aromataze group</arm_group_label>
    <arm_group_label>classic group</arm_group_label>
    <other_name>choriomon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infertlity indicated for ICSI

          -  Ovarian factor

          -  Tubal factor

          -  Unexplained infertility

          -  poor responders

        Exclusion Criteria:

          -  Expected high responder

          -  Endometriosis

          -  Male and uterine factors

          -  Ovarian mass or cyst
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Minia University</name>
      <address>
        <city>Minia</city>
        <zip>61519</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril. 2002 Apr;77(4):776-80.</citation>
    <PMID>11937133</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>Reham Elkhateeb</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <keyword>aromataze inhibitor, poor responder ,induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

